Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
about
Screening: A risk-based framework to decide who benefits from screeningProstate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries.Vitamin K epoxide reductase regulation of androgen receptor activity.When should active surveillance for prostate cancer stop if no progression is detected?Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.The role of peroxisome proliferator-activated receptor gamma in prostate cancer.US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.Insights from the PLCO trial about prostate cancer screening.Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.Health state utilities among contemporary prostate cancer patients on active surveillance.Cost implications of PSA screening differ by age.
P2860
Q33894116-18D23A90-55BA-4140-8CCF-DEC9257A4417Q37554581-6CE8F6FD-FD4C-4E05-A535-59F66EC9E1EEQ37706708-40FF80C6-6184-4744-827D-41A3F5181D08Q38832126-5E841E8F-33BA-447C-BDFE-39F6F2741CD7Q39262504-DE499642-9FD9-4A8C-9F38-C1245A7C6AEBQ39361760-6CA4D4B9-E47E-49C2-8267-80C74C0F7707Q44449601-860BE188-B577-4BD3-9FC7-3B3CDCAED77AQ47324732-7A858A4D-0A45-4168-AFED-A9F258F764BAQ48100525-BE034FED-9210-4138-B206-7DA56CDE5606Q48185732-CB6B6904-0F04-4D9A-94FE-66CDA81D5AEEQ48217159-734E38A7-56A7-438B-8523-4E3D20C970B5Q48681310-7A360AA9-CB67-49C3-8957-C5ADE54B38CDQ52624211-F6F3156E-3ACD-4023-B3AA-9A210FC848A9Q54957979-19EB98EA-75BD-47BD-9F42-5FCD92D78543Q55032029-8C6C4F1B-36F9-4428-9B80-317142307BEC
P2860
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Economic Analysis of Prostate- ...... Selective Treatment Strategies
@en
Economic Analysis of Prostate- ...... elective Treatment Strategies.
@nl
type
label
Economic Analysis of Prostate- ...... Selective Treatment Strategies
@en
Economic Analysis of Prostate- ...... elective Treatment Strategies.
@nl
prefLabel
Economic Analysis of Prostate- ...... Selective Treatment Strategies
@en
Economic Analysis of Prostate- ...... elective Treatment Strategies.
@nl
P2093
P2860
P1433
P1476
Economic Analysis of Prostate- ...... Selective Treatment Strategies
@en
P2093
John L Gore
Joshua A Roth
Matthew R Cooperberg
Roman Gulati
Ruth Etzioni
P2860
P304
P356
10.1001/JAMAONCOL.2015.6275
P577
2016-03-24T00:00:00Z